Johnson, Melissa J.
Tommerdahl, Kalie L.
Vinovskis, Carissa
Waikar, Sushrut
Reinicke, Trenton
Parikh, Chirag R.
Obeid, Wassim
Nelson, Robert G.
van Raalte, Daniel H.
Pyle, Laura
Nadeau, Kristen J.
Bjornstad, Petter
Funding for this research was provided by:
National Institute of Diabetes and Digestive and Kidney Diseases (K23-DK116720)
Juvenile Diabetes Research Foundation United States of America (2-SRA-2018-627-M-B, 3-SRA-2022-1097-M-B)
Article History
Received: 24 September 2021
Revised: 29 January 2022
Accepted: 31 January 2022
First Online: 14 March 2022
Declarations
:
: The CASPER and Renal-HEIR cohorts have intentionally harmonized study protocols and were both approved by the Colorado Multiple Institutional Review Board (COMIRB).
: Participants and/or guardians provided written informed assent and/or consent, as appropriate.
: Not applicable.
: M.J.J., K.L.T., C.V., S.W., T.R., W.O., R.G.N., L.P., and K.J.N. have no relationships relevant to the contents of this paper to disclose. C.R.P. reports serving as a member of the advisory board of and owning equity in RenalytixAI. He also serves as a consultant for Genfit and Novartis. D.H.vR. has served as a consultant and received honoraria from Boehringer Ingelheim and Eli Lilly, Merck, Novo Nordisk, and Sanofi and has received research operating funds from AstraZeneca, Boehringer Ingelheim-Eli Lilly Diabetes Alliance, MSD, and Novo Nordisk. P.B. reports serving as a consultant for AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, LG Chemistry, Sanofi, Novo Nordisk, and Horizon Pharma. P.B. also serves on the advisory boards of AstraZeneca, Bayer, Boehringer Ingelheim, Novo Nordisk, and XORTX.